Publication details

Diagnostika a léčba BCR/ABL-negativních myeloproliferativních onemocnění-principy a východiska doporučení CZEMP

Title in English Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases – principles and rationale of CZEMP recommendations
Authors

SCHWARZ J. PENKA Miroslav CAMPR V. POSPÍŠILOVÁ D. KŘEN Leoš NOVÁKOVÁ L. BODZÁSOVÁ C. BRYCHTOVÁ Yvona ČERNÁ O. DULÍČEK P. JONÁŠOVÁ A. KISSOVÁ Jarmila KOŘÍSTEK Zdeněk SCHÜTZOVÁ M. VONKE I. WALTEROVÁ L.

Year of publication 2011
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords Ph- myeloproliferative disease; essential thrombocythemia; polycythaemia vera; primary myelofibrosis; diagnosis; risk factors; treatment algorithm; hydroxyurea; anagrelide; hematopoietic stem cell transplantation
Description In 2009, the recommendations of the Czech Collaborative Group for Ph- Myeloproliferative Diseases (CZEMP) for diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases (MPD), i.e. essential thrombocythemia (ET), polycythaemia vera (PV) and primary myelofibrosis (PMF) were updated and extended. The present article gives the rationale of the recommendations in full detail. The CZEMP diagnostic criteria for ET and PMF are based on histopathological (HP) findings, which must unconditionally be in line with the given clinical and laboratory characteristics of ET or of a certain stage of PMF, respectively. The platelet count is not decisive for diagnosis. In cases lacking an adequately taken and read HP finding, the Polycythemia Vera Study Group (PVSG) criteria are recommended.

You are running an old browser version. We recommend updating your browser to its latest version.

More info